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AbstrACt
Introduction Home-based cardiac rehabilitation 
may overcome suboptimal rates of participation. The 
overarching aim of this study was to assess the feasibility 
and acceptability of the novel Rehabilitation EnAblement in 
CHronic Hear Failure (REACH-HF) rehabilitation intervention 
for patients with heart failure with preserved ejection 
fraction (HFpEF) and their caregivers.
Methods and results Patients were randomised 1:1 to 
REACH-HF intervention plus usual care (intervention group) 
or usual care alone (control group). REACH-HF is a home-
based comprehensive self-management rehabilitation 
programme that comprises patient and carer manuals 
with supplementary tools, delivered by trained healthcare 
facilitators over a 12 week period. Patient outcomes were 
collected by blinded assessors at baseline, 3 months 
and 6 months postrandomisation and included health-
related quality of life (primary) and psychological well-
being, exercise capacity, physical activity and HF-related 
hospitalisation (secondary). Outcomes were also collected 
in caregivers. We enrolled 50 symptomatic patients with 
HF from Tayside, Scotland with a left ventricular ejection 
fraction ≥45% (mean age 73.9 years, 54% female, 100% 
white British) and 21 caregivers. Study retention (90%) and 
intervention uptake (92%) were excellent. At 6 months, 
data from 45 patients showed a potential direction of 
effect in favour of the intervention group, including the 
primary outcome of Minnesota Living with Heart Failure 
Questionnaire total score (between-group mean difference 
−11.5, 95% CI −22.8 to 0.3). A total of 11 (4 intervention, 
7 control) patients experienced a hospital admission over 
the 6 months of follow-up with 4 (control patients) of these 
admissions being HF-related. Improvements were seen 
in a number intervention caregivers' mental health and 
burden compared with control.
Conclusions Our findings support the feasibility and 
rationale for delivering the REACH-HF facilitated home-
based rehabilitation intervention for patients with HFpEF 
and their caregivers and progression to a full multicentre 
randomised clinical trial to test its clinical effectiveness 
and cost-effectiveness.
trial registration number ISRCTN78539530.
IntroduCtIon 
Epidemiological data show that approxi-
mately half of those patients with clinical 
features of heart failure (HF) have preserved 
strengths and limitations of this study
 ► Rehabilitation EnAblement in CHronic Heart Failure 
(REACH-HF) is the first comprehensive home-based, 
self-management cardiac rehabilitation intervention 
for patients with heart failure with preserved ejec-
tion fraction (HFpEF) and their caregivers.
 ► The findings of this pilot study support the feasibility 
and acceptability of the home-based REACH-HF re-
habilitation intervention in patients with HFpEF and 
their caregivers and indicate that it is feasible to 
recruit and retain participants in a randomised trial 
with follow-up.
 ► Potential favourable impacts of the REACH-HF inter-
vention on caregiver mental health and measures of 
burden were observed in this pilot study.
 ► This study was not designed or powered to defini-
tively assess the efficacy or safety of the REACH-HF 
intervention in HFpEF.
 ► Generalisability of this study’s findings is limited, 
given it was based in a single centre.
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ejection fraction (HFpEF).1 In contrast to HF with 
reduced ejection fraction (HFrEF), the prevalence of 
HFpEF is increasing.2 Importantly, the substantial burden 
from HFpEF appears to be similar to HFrEF, measured 
by exercise intolerance, poor health-related quality of 
life (HRQoL), mortality, increased hospital admissions 
and higher healthcare costs.3 Although drug and device 
therapy have helped to improve outcomes in HFrEF, prog-
nosis in HFpEF remains unchanged, with no large-scale 
randomised trial demonstrating significant treatment 
benefits that alter the natural course of HFpEF or lower 
mortality.4 5 However, systematic reviews and meta-anal-
yses have shown promising evidence for the benefit of 
exercise-based cardiac rehabilitation (CR) in HFpEF.6 7 
A recent meta-analysis of eight randomised trials in 317 
patients with HFpEF found exercise-based CR signifi-
cantly improved exercise capacity and HRQoL compared 
with usual care.7 The CR programmes undertaken in 
these trials were predominantly group-based, supervised 
and delivered in centre-based settings.
Participation of patients with HF in CR remains subop-
timal.8 9 A UK survey found that only 16% of CR centres 
provided an HF programme; commonly cited reasons 
for the lack of CR provision were a lack of resources and 
exclusion from commissioning agreements.9 Two main 
reasons given by patients for failing to take part in CR are 
difficulties with regular attendance at their local hospital 
centre and reluctance to join group-based classes.9
There is increasing recognition of the possibility of 
alternative delivery models of CR, such as home-based 
programmes, in order to overcome suboptimal rates of 
CR uptake seen with HF.10 11 Facilitated home-based CR 
has been shown to provide similar benefits to centre-
based CR in terms of clinical and HRQoL outcomes at 
equivalent cost for those with HF and following myocar-
dial infarction and revascularisation.11 12
The Rehabilitation EnAblement in CHronic Heart 
Failure (REACH-HF) programme of research was designed 
to develop and evaluate a home-based comprehensive 
self-management rehabilitation intervention, including a 
self-care manual, an exercise programme, and facilitation 
by health professionals designed to improve self-man-
agement and HRQoL in people with HF.13 14 In addition 
to REACH-HF, the intervention includes a ‘Family and 
Friends Resource’ designed to support caregivers.
The overarching aim of this study was to assess the 
feasibility of undertaking a definitive randomised trial to 
assess the clinical effectiveness and cost-effectiveness of 
the REACH-HF intervention in patients with HFpEF and 
their caregivers. Specific objectives of the study were to: 
(1) Assess the acceptability of the study design and proce-
dures to participants (patients and caregivers). (2) Assess 
feasibility and experience of the delivery of intervention 
for participants and healthcare professional facilitators. 
(3) Identify barriers to participation in the interven-
tion and study procedures. (4) Inform a definitive study 
sample size. (5) Assess methods for the collection of data 
including resource use and costs. (6) Assess the fidelity of 
the delivery of the REACH-HF intervention by healthcare 
professional facilitators.
Methods
The study design and methods have been described in 
the published study protocol.14 The study is reported in 
accordance with the Consolidated Standards of Reporting 
Trials (CONSORT) extension for pilot trials.15
design
The REACH-HFpEF pilot study was a single-centre 
(Tayside, Scotland) two-group randomised controlled 
trial with parallel mixed-methods feasibility evaluation 
and assessment of costs. Participants were individually 
randomised in a 1:1 ratio to the REACH-HF intervention 
plus usual care (intervention group) or usual care alone 
(control group). Given the nature of the REACH-HF 
intervention, it was not possible to blind participants or 
those involved in the provision of care. However, the stat-
istician (FCW) undertaking the data analysis was blinded 
to treatment allocation and we also blinded researchers 
undertaking collection of outcome data to minimise 
potential bias. We assessed the fidelity of blinding by 
asking outcome assessors at each follow-up visit to guess 
patient group allocation. Unblinding of groups did not 
take place until after data analysis and the blinded results 
had been presented to the Trial Management Group and 
interpretation of results was agreed.
study population
The study population included patients and their care-
givers. Participating patients were aged 18 years or older 
and had a confirmed diagnosis of HFpEF on echocardi-
ography, radionuclide ventriculography or angiography 
(ie, left ventricular ejection fraction ≥45% within the 
last 6 months prior to randomisation). Patients who had 
undertaken CR within 6 months prior to enrolment were 
excluded, as were patients with a contraindication to 
exercise testing or exercise training (with consideration 
of adapted European Society of Cardiology guidelines 
for HF).14 16 Participating caregivers were aged 18 years 
or older and provided unpaid support to participating. 
Patients who did not have an identified caregiver were 
able to participate, as were those whose caregiver was not 
willing to participate in the study.
Intervention
The REACH-HF intervention is described in detail else-
where.17 In summary, REACH-HF is a comprehensive 
self-management programme informed by evidence, 
theory and service user perspective. It comprises the 
‘Heart Failure Manual’ (REACH-HF manual), relaxation 
compact disc (CD), chair-based exercise digital versatile 
disc (DVD), a ‘Progress Tracker’ tool for patients and 
a ‘Family and Friends Resource’ for caregivers. Partic-
ipating patients and caregivers worked through the 
REACH-HF manual over a 12-week period with facilitation 
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by two trained cardiac nurses. The facilitators provided 
support as needed of which at least one was face to face 
and two were by telephone contacts. The REACH-HF 
manual incorporates five core informative and interactive 
elements covering a wide range of topics relating to living 
with/adapting to living with HF, and includes:
1. A progressive exercise training programme, tailored 
according to initial fitness assessments, delivered as a 
walking programme or a chair-based exercise DVD, or 
a combination of the two (as selected by the patient).
2. Managing stress/breathlessness/anxiety.
3. HF symptom monitoring.
4. Taking medication. 
5. Understanding HF (and why self-management helps).
The REACH-HF manual was designed for patients with 
HFrEF (in terms of coverage of medication and explana-
tions of condition). There was limited evidence to guide 
the development of the REACH-HF manual for patients 
with HFpEF. Thus it was adapted for this pilot study to 
allow evaluation in patients with HFpEF. The majority of 
the self-management advice in all other sections of the 
REACH-HF manual is relevant to all patients with HF 
and corresponds to national HF guidelines.18 19 The core 
priorities for caregiver elements of the intervention were:
1. To facilitate improvement in patient HRQoL by help-
ing them to achieve the core priorities for change.
2. To improve HRQoL for caregivers by acting to main-
tain their own health and well-being.
usual care
Both intervention and control group patients received 
usual medical management for HF according to current 
guidelines.18 19
outcome measures and follow-up
We collected the following pilot study outcomes: recruit-
ment rate for participants (patients and caregivers) across 
the various recruitment pathways; attrition and loss to 
follow-up; completeness of participant outcome measures 
at follow-up; fidelity of the REACH-HF manual delivery 
by intervention facilitators (sample of patient-facilitator 
contacts for a sample of six patients were audio recorded 
and independently reviewed using a 13-item checklist 
(developed by CJG and JW) by two researchers (KS and 
Karen Coyle)); acceptability of the intervention (via face-
to-face semistructured interviews with a purposive sample 
of 15 patients, 7 caregivers and both facilitators at the end 
of the intervention delivery period); and acceptability of 
study participation to participants (via interviews and 
questionnaires).
The following participant outcomes proposed for a 
future definitive trial were collected at baseline (preran-
domisation) and follow-up at 4 months and 6 months 
postrandomisation:
Patients: disease-specific HRQoL (Minnesota 
Living with Heart Failure Questionnaire (MLHFQ) 
(primary outcome)20 and Heart Related Quality of Life 
(HeartQoL) Questionnaire);21 clinical events (all-cause 
mortality, hospital admission related to HF and not 
related to HF (relatedness was independently adju-
dicated by a panel of three cardiologists)); exercise 
capacity (incremental shuttle walking test (ISWT));22 
physical activity level (GeneActive accelerometry over 
a 7-day period);23 psychological well-being (Hospital 
Anxiety and Depression Scale Questionnaire, HADS);24 
generic HRQoL (EQ-5D-5L questionnaire);25 Self-care 
of HF Index Questionnaire (SCHFI);26 healthcare util-
isation (primary and secondary care contacts, social 
care contacts and relevant medication usage, reported 
by patient participants); and safety outcomes (serious 
adverse events).
Caregivers: Caregiver Burden Questionnaire for HF 
(CBQ-HF);27 Caregiver Contribution to SCHFI Ques-
tionnaire (CC-SCHFI);26 Family Caregiver Quality of Life 
Scale Questionnaire;28 Generic HRQoL (EQ-5D-5L);25 
and psychological well-being (HADS).24
data analysis
Our planned recruitment target of 50 patients allowed us 
to achieve the feasibility aims and objectives of this study, 
that is, an estimate of attrition, estimates of the SD of the 
primary and secondary outcomes to inform power for a 
future definitive trial, and sufficient numbers for qualita-
tive interviews.
We report the mean and SD (or relevant summary statis-
tics) for both groups for all patient and caregiver outcomes 
at each follow-up point and the mean (and 95% CIs) for 
the between-group difference in outcomes at 6-month 
follow-up using linear regression models adjusting for base-
line outcome. Given the pilot nature of this trial, we do not 
report p values for the comparison of outcomes between 
groups. All analyses are based on the intention-to-treat 
principle (patients are analysed according to their original 
random allocation) using observed data only.
Data on patient resource use related to health and 
social care were collected using a standardised resource 
use questionnaire at baseline (for previous 6 months) 
and at 4-month and 6-month follow-ups. Unit costs per 
item of resource use were obtained from published esti-
mates and where necessary inflated to 2016 prices using 
the Healthcare and Community Health Services index 
(see online supplementary eTable 1).29 These unit costs 
were then applied to the resource use reported at patient 
level to estimate the delivery costs associated with the 
REACH-HF manual, and the total costs associated with 
health and social care at baseline and over the 6-month 
follow-up. As with clinical outcome, costs are presented 
descriptively. EQ-5D-3L utilities were obtained using 
existing crosswalk values from EQ-5D-5L.30 All outcomes 
and costs analyses were conducted using Stata (V.14.2; 
StataCorp, College Station, Texas, USA). Patient, care-
giver and facilitator interviews were transcribed verbatim 
and analysed using thematic analysis and will be fully 
reported elsewhere.31
 o
n
 16 August 2019 at University of G
lasgow. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019649 on 9 April 2018. Downloaded from 
4 Lang CC, et al. BMJ Open 2018;8:e019649. doi:10.1136/bmjopen-2017-019649
Open Access 
results
recruitment and retention of patients and caregivers and 
acceptability of trial design
Study enrolment, allocation and follow-up of study 
participants are summarised in the CONSORT flow 
diagram shown in figure 1. Between April 2015 and 
June 2016, 225 potential patients were approached and 
50 were randomised (intervention group 25; control 
group 25) that is, 22% (95% CI 17% to 28%) of patients 
approached. The original forecast was a recruitment rate 
of five patients per month. However, the actual recruit-
ment rate during the trial was 4.5 patients per month, 
resulting in a 1-month extension to the period of recruit-
ment. A caregiver was recruited in connection with 21 
(42%) patient participants (intervention group 11; 
control group 10).
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) flow chart.
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At the 6-month follow-up, 5 out 50 (10%, 95% CI 3% 
to 22%) patients were lost to follow-up. Seventeen out 
of the 21 recruited caregivers provided follow-up data at 
6 months.
Patients and caregivers rated a high level of satisfaction 
with their participation in the trial (see online supple-
mentary eTable 2).
baseline characteristics of patients and caregivers
There was evidence of imbalance between intervention 
and control group patients in terms of their baseline 
demographic characteristics (see table 1). Compared 
with the control group, the intervention group included 
a higher proportion of women, and lower proportions of 
patients with an ischaemic diagnosis, with atrial flutter/
atrial fibrillation, and with chronic renal failure; also, the 
intervention group had a younger mean age. Caregivers 
were typically the partner or children of patients, were 
of a younger mean age than participating patients and 
predominantly female.
Table 1 Baseline demographic characteristics
(A) Patient characteristics
Intervention 
n=25 mean (SD) 
or n (%)
Control n=25 
mean (SD) or 
n (%)
Gender: male 9 (36) 14 (56)
Age (years) 71.8 (9.9) 76.0 (6.6)
BMI (kg2/m) 32.1 (6.3) 32.2 (5.3)
Ethnic group: white 25 (100) 25 (100)
Relationship status:
  Single 4 (16) 2 (8)
  Married 14 (56) 8 (32)
  Divorced/civil 1 (4) 3 (12)
  Partnership dissolved/widowed 6 (24) 12 (48)
Domestic residence:
  Live alone 9 (36) 14 (56)
  Spouse/partner only 14 (56) 8 (32)
  Spouse/partner and child > 0 (0) 2 (8)
  18 years other adult family 
members only
2 (8) 1 (4)
Smoking status
  Never smoked 2 (8) 2 (8)
  Ex-smoker 15 (60) 14 (56)
  Current smoker 8 (32) 9 (36)
NYHA status
  Class I 1 (4) 1 (4) 
  Class II 15 (60) 16 (64) 
  Class III 9 (36) 8 (32) 
  Class IV 0 (0) 0 (0) 
Cause of heart failure*
  Ischaemic 8 (32) 16 (64) 
  Non-ischaemic 16 (64) 8 (32) 
  Unknown 1 (4) 1 (4) 
Number of comorbidities
  0 7 (28) 12 (48) 
  1 15 (60) 6 (24) 
  2 3 (12) 4 (16) 
  3 0 2 (8) 
  4 0 1 (4) 
Previous myocardial infarction 4 (16) 5 (20)
Previous atrial fibrillation/atrial 
flutter
6 (24) 13 (52)
Hypertension 18 (72) 14 (56)
Diabetes mellitus 9 (36) 6 (24)
Chronic renal impairment 3 (13) 10 (40)
Time since diagnosis of heart failure (years)
  <1 6 (24) 4 (16)
  1 to 2 7 (28) 7 (28)
  >2 12 (48) 15 (60)
Medication
  β-blocker 18 (72) 13 (52)
Continued
(A) Patient characteristics
Intervention 
n=25 mean (SD) 
or n (%)
Control n=25 
mean (SD) or 
n (%)
  Angiotensin 2 receptor 
antagonist 
7 (28) 7 (28) 
  ACE inhibitor 11 (44) 14 (56)
Main activity:
  In employment or self-
employment
0 (0) 1 (4)
  Retired 22 (88) 24 (96) 
  Unemployed 2 (8) 0 (0)
  Other 1 (4) 0 (0)
Education
  Postschool 7 (28) 7 (28)
  Degree 5 (20) 5 (20)
Pro-BNP levels
  ≤2000 pg/mL 23 (92) 22 (88)
  >2000 pg/mL 2 (8) 3 (12)
(B) Caregiver characteristics
Intervention 
n=11† mean (SD) 
or n (%)
Control n=10 
mean (SD) or 
n (%)
Gender: male 3 (30) 2 (20)
Age (years) 59.3 (14.0) 64.8 (11.6)
Relationship to patient
  Partner 4 (40) 6 (60)
  Son/daughter 3 (30) 4 (40)
  Sibling 2 (20) 0 (0)
  Friend 1 (10) 0 (0)
*Cause of HF determined by principal investigator.
†One caregiver withdrew shortly after randomisation and did not 
provide baseline data.
BNP, B-tyep Natriuretic Peptide; NYHA, New York Heart Association. 
Table 1 Continued 
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Completion of outcome measures by patients and caregivers 
and fidelity of blinding by outcome assessors
We collected data from 45/50 patients (90%, 95% CI 
78% to 97%) at the 6-month follow-up on MLHFQ, our 
proposed primary outcome. Levels of completion of 
patient secondary outcomes and caregiver outcomes were 
consistently high (≥76% of participants for all outcomes). 
The one exception was ISWT, which had notably lower 
level of completion (35 (78%) patients at the 4-month 
follow-up and 33 (73%) patients at the 6-month follow-up).
Outcome assessors correctly guessed patient group allo-
cation in 22% of cases (10/45) at 4 months and 20% of 
cases (19/45) at 6 months, indicating that blinding was 
likely to have been maintained.
Acceptability of patients, carers and facilitators of the reACh-
hF intervention and fidelity of intervention delivery by 
facilitators
Qualitative interviews and observations of the patients' 
and caregivers' interactions with the facilitator 
indicated high levels of satisfaction, acceptability and 
the feasibility of delivering the REACH-HF interven-
tion in patients with HFpEF (see online supplementary 
eTable 3). One of the most highly valued elements of 
REACH-HF by participants was the role of the facili-
tator, who was seen to act as an educator, a source of 
emotional support and reassurance as well as a moti-
vator and enabler.
Of the six patients selected for inclusion, a total 
of ~45 hours of patient-facilitator interaction was used 
for analysis. Fidelity scoring indicated adequate delivery 
(defined as a score of 3 or more) for most aspects of the 
intervention by the two facilitators (see online supple-
mentary eTable 4). Of the six patients selected for 
inclusion, a total of ~45 hours of patient-facilitator 
interaction was used for analysis. Mean score for items 
9 (addressing emotional consequences of being a care-
giver) and 11 (caregiver health and well-being) was less 
than 3.
Table 2 Rehabilitation EnAblement in CHronic Heart Failure (REACH-HF) intervention delivery: healthcare resource use and 
costs
Number of 
patient contacts, 
mean (SD)
Duration of 
patient contacts' 
contact (min), 
mean (SD)
Duration of 
facilitator non-
contact planning 
(min), mean (SD)
Duration of 
facilitator travel 
(min), mean (SD)
Face-to-face contacts/patient 5.1 (1.5) 60.6 (29.6) 17.2 (24.4) 40.2 (37.4)
Telephone contacts/patient 1.1 (1.3) 7.7 (4.0) 8.0 (9.5)
Total contacts/patient 6.2 (1.6)
Total time, face-to-face contacts 308.9 (123.3)
Total time, telephone contacts 8.8 (10.3)
Total facilitator planning/non-contact time, 
face-to-face, minutes
87.4 (55.8)
Total facilitator planning/non-contact time, 
telephone, minutes
9.1 (12.6)
Overall total time input, time 414.2 (145.4)
Cost per patient*, 
mean (SD)
Estimated total HF facilitator cost £303.64 (£106.59)
Other resource use/costs
  Consumables (1 × manual) £25.00 
  DVDs (×2, at £7.50 each) £15.00 
  Distribution of HF facilitator training 
costs, per participant † 
£18.97 
Estimated total delivery cost of the REACH-
HF intervention
£362.61
*Unit costs—staff: Staff grade equivalent to ‘Community Nurse’ (includes district nursing sister, district nurse) and Nurse Specialist 
(community), from Curtis and Burns, Unit Costs of Health and Social Care 2016, p141-142. Based on Agenda for Change band 6 (staff salary 
at £32 114 per annum). Estimated cost per hour = £44 (Curtis and Burns, 2016); Includes salary, salary on costs, overheads (management 
costs and non-staff costs (including travel/transport)), capital overheads, and excludes costs for qualifications.
†Training cost per REACH-HF facilitator, specific to delivery of the REACH-HF intervention, are estimated at £1897 (involving 3 days, that is, 
24 hours training at £44/hour; costs for trainer/s per trainee at £366, assuming eight trainees per 3-day course, and trainers at Agenda for 
Change, Band 8a, £61/hour (Curtis and Burns, 2016); cost for REACH-HF facilitator manual at £400 each; plus estimate of consumables for 
training sessions). These costs are distributed across the first 100 participants/patients receiving the intervention, resulting in an estimate of 
£18.97 per participant.
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Patient adherence to the reACh-hF intervention
Twenty-three of the 25 (92%) intervention patients met 
our minimum adherence criteria of attendance, that 
is, attendance at the first face-to-face meeting with the 
facilitator and at least two further facilitator contacts 
(either face-to-face or telephone). In these patients, the 
mean number of facilitator contacts was 6.2 (SD 1.6), the 
majority of which was face-to-face contacts (mean 5.1; SD 
1.5) and the remainder was telephone contacts (mean 
1.1, SD 1.3) (see table 2).
PArtICIPAnt outCoMes
Patients
Patient outcome results at baseline, and 3-month and 
6-month follow-ups, and between-group differences 
at the 6-month follow-up are shown in table 3 (see 
online supplementary eTable 5 for baseline follow-up 
within group changes). At 6 months, a number of 
patient outcomes potential direction of effect in favour 
of intervention, including Minnesota Living With Heart 
Failure Questionnaire (MLWHFQ) total score (figure 2) 
(between-group mean difference: −11.5, 95% CI −22.8 
to 0.3), HeartQoL Global Score (0.5, 95% CI 0.0 to 0.9), 
EQ-5D-3L Utility Index (0.11, 95% CI −0.04 to 0.26), 
HADS Depression Score (−1.5, 95% CI −3.4 to 0.3) and 
SCHFI Maintenance Score (9.5, 95% CI 2.5 to 17.3). The 
directions of possible intervention effects were less clear 
for the outcomes of ISWT and level of physical activity.
At the 6-month follow-up, 11 (4 intervention, 7 control) 
patients experienced a hospital admission with 4 (all 
control) of these admissions being HF-related. All these 
serious adverse events were considered to be unrelated 
to the study processes or to the REACH-HF intervention. 
One control patient died related to HF shortly after the 
6-month follow-up.
Caregivers
Caregiver outcome results at baseline and 3-month and 
6-month follow-ups are shown in table 4 (see online 
supplementary eTable 6 for within-group results). There 
were indications of a favourable intervention effect for 
some outcomes including HADS and CBQ-HF emotional 
and CC-SCHFI maintenance domain scores.
healthcare utilisation and intervention costs
The average cost of the REACH-HF intervention per 
patient was estimated to be £362.61. The intervention 
cost breakdown is provided in table 2. The wider health-
care and societal utilisation and costs for intervention and 
control groups are summarised in online supplementary 
eTable 7.
dIsCussIon
The findings of this pilot study support the feasibility 
and acceptability of the home-based REACH-HF reha-
bilitation intervention in patients with HFpEF and their 
caregivers, and indicate that it is feasible to recruit and 
retain participants in a randomised trial of 6 months 
follow-up. The intervention was well received by patients, 
caregivers and healthcare facilitators and interven-
tion adherence was good. At follow-up, compared with 
controls, a number of patient outcomes showed a poten-
tial direction of effect in favour of the intervention group, 
including our proposed primary outcome of disease-spe-
cific HRQoL, MLWHFQ. We also saw potentially favour-
able impacts of the REACH-HF intervention on caregiver 
mental health and measures of burden.
The promising results of this study support the emerging 
evidence of the impact of exercise-based CR interventions 
in HFpEF.6 7 A recent meta-analysis of randomised trials 
(ranging in sample size from 25 to 198 patients) suggest 
improvements in exercise capacity and HRQoL following 
intervention compared with control.7 However, these 
previous studies have predominantly been supervised and 
delivered in centre-based settings. Participation in centre-
based CR has been suboptimal, with national practice 
surveys indicating that fewer than 20% of eligible patients 
with HF may be receiving exercise-based CR.8 Therefore, 
Figure 2 Minnesota Living With Heart failure Questionnaire 
(MLHFQ) outcomes at baseline and at 4-month and 6-month 
follow-ups.
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there is increasing interest in home-based programmes 
that have the potential to overcome these suboptimal 
rates of CR participation seen with HF.10 11 To our knowl-
edge, REACH-HF is the first comprehensive self-manage-
ment CR intervention for patients with HFpEF and their 
caregivers that is home-based, with facilitation by health-
care professionals and whose development is informed by 
evidence, theory and input from service users—patients 
and clinicians.
The mechanism by which CR improves HRQoL in 
HFpEF remains unclear.32 While exercise training has been 
shown to improve cardiac (systolic and diastolic) function 
in patients with HFrEF, studies have failed to show such 
consistent benefits in HFpEF.6 7 Instead exercise training 
may improve exercise tolerance in HFpEF through periph-
eral mechanisms leading to an improved oxygen extraction 
in the active skeletal muscles.33 Such improvements are 
likely to improve patient physical capacity and hence 
the physical component of HRQoL. Poor mental health, 
including depression in patients with HF is common and 
may be under-recognised and undertreated in cardiac 
populations such as HFpEF. This is supported by the base-
line HADS Scores in this study indicating mild to moderate 
symptoms of depression and anxiety in a proportion of 
patients (and caregivers). A recent Cochrane review has 
shown comprehensive CR, including elements of stress 
management and exercise training, can have significant 
positive effects in terms in reductions in depression and 
anxiety of myocardial infarction and postrevascularisation 
populations.34 The observed trend towards a reduction in 
depression and anxiety scores with the REACH-HF inter-
vention points towards a possible basis of improvement in 
the mental component of HRQoL.
This study has a number of limitations. First, the study 
was not designed or powered to definitively assess the 
efficacy or safety of the REACH-HF intervention in 
HFpEF. Second, generalisability of this study’s findings 
is limited, given it was based in a single centre. Thirdly, 
there was evidence of imbalances between intervention 
and control groups in their demographic characteristics 
and outcome scores at baseline. Fourthly, patient and 
clinician blinding was not possible in this study because 
of the nature of the intervention, although we did 
demonstrate that it was possible to blind outcome asses-
sors to group allocation. Finally, the open label design 
of the study may have resulted in improvements in 
patient-reported outcomes in intervention participants 
as the result of placebo effects. However, we would note 
there was some evidence of fewer clinical events in the 
intervention group at 6 months. Given these limitations 
and the pilot nature of this trial, our findings should 
therefore be considered preliminary, and encouraging 
trends require confirmation in a larger, adequately 
powered clinical trial.
Implications for planning a future trial
Based on the Minnesota Living With Heart Failure 
Questionnaire (MLWHFQ) total score as the primary 
outcome, a full trial comparing the REACH-HF plus 
usual care versus usual care alone would require 
recruitment of 210 patients with HFpEF per group. This 
estimate is based on detecting a minimum clinically 
important difference on the MLWHFQ of 5 points,20 a 
SD of 25 points (as seen in this pilot trial, see table 1), a 
within-patient correlation of 0.8 (between baseline and 
the 6-month follow-up calculated from data from this 
pilot) and an assumed attrition rate of 10% (as seen in 
this pilot trial, see figure 1), at 90% power and 5%  α 
level.
Two issues raised in this pilot that deserve consid-
eration for a full trial include the choice of exercise 
test and the assessment of patient adherence to the 
REACH-HF intervention. In interviews, a number of 
patients in this study expressed the opinion that they 
found undertaking the ISWT an unpleasant experience; 
12 of 45 (27%) patients were not able to undertake 
ISWT at the 6-month follow-up. This loss to follow-up 
my have resulted in bias in our assessment of exercise 
capacity over time and in our comparison of groups. 
Assessing and ensuring adequate levels of intervention 
adherence is a challenge in self-directed home-based 
interventions, such as REACH-HF.11 Levels of patient 
attendance at face-to-face or telephone contacts with 
healthcare facilitators indicated good levels of inter-
vention adherence. Patients were also asked to docu-
ment changes in their health behaviours in a ‘Patient 
Tracker’ diary over the duration of the study. We need 
to examine if these diaries support our conclusion of 
good intervention adherence seen from facilitator 
contacts. It will be important to revisit these two issues 
in the design and planning of a future full trial.
In summary, the findings from this pilot study indi-
cate that the REACH-HF home-based comprehensive 
self-management CR intervention facilitated by health-
care professionals is feasible, acceptable and suggests 
promising effects on patients with HFpEF and caregiver 
outcomes. This pilot study will help inform the funding 
application for a fully powered multicentre randomised 
trial to assess the clinical effectiveness and cost-effective-
ness of the novel REACH-HF intervention in patients 
with HFpEF and their caregivers.
PersPeCtIves
Competency in medical knowledge
The present findings support that patients with HFpEF 
have a substantial burden with exercise intolerance and 
a poor HRQoL.
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